Association between tumor necrosis factor inhibitor (TNFi) therapy and changes in C-reactive protein (CRP), blood pressure, and alanine aminotransferase (ALT) among patients with psoriasis, psoriatic arthritis, or rheumatoid arthritis - 17/04/15
This study was sponsored by Immunex, a wholly owned subsidiary of Amgen, and by Wyeth, which was acquired by Pfizer Inc in October 2009. Amgen had a role in the following: design and conduct of the study; analysis and interpretation of the data; and review or approval of the manuscript. Amgen did not have a role in the collection or management of the data. |
|
Disclosure: Dr Anthony was employed by Amgen during the study, and she owns stock of Amgen. Dr Wu received research grants from AbbVie, Amgen, Coherus Biosciences, Eli Lilly, Janssen, Merck, Novartis, Pfizer, Regeneron, and Sandoz; he is a consultant for AbbVie, Amgen, DUSA Pharmaceuticals, Eli Lilly, and Pfizer. Drs Rowan and Bebchuk have no conflicts of interest to declare. |
Vol 72 - N° 5
P. 917-919 - mai 2015 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?